Trials / Unknown
UnknownNCT04936490
Crocin Supplementation in CSCR
Efficacy and Safety of Crocin Supplementation in Patients With Central Serous Chorioretinopathy (CSCR)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Shiraz University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Preclinical and clinical evidence support the protective effect of crocin on different pathologic pathways involved in central serous chorioretinopathy (CSCR). They involve inflammation, oxidative stress, mineralocorticoid pathway, and also stress-related injuries. It also showed that crocin has a protective effect on the retinal pigmented epithelium (RPE) layer. Based on the mentioned evidence the study designed to evaluate the efficacy and safety of 2-month crocin supplementation (15 mg/d) in 40 patients with CSCR in a randomized controlled blinded clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Crocin | 15 mg/d |
| DRUG | Placebo | 15 mg/d |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2021-11-30
- Completion
- 2021-11-30
- First posted
- 2021-06-23
- Last updated
- 2021-10-28
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT04936490. Inclusion in this directory is not an endorsement.